Long Shortz with Race: Major advancements in lung cancer and AML drugs

Host Tylah Tully chats to Race Oncology (ASX:RAC) CEO Dr Daniel Tillett to unpack two major new clinical programs for RC220 in lung cancer and AML.

He explains the scientific breakthrough that revealed how RC220 truly works, why its dual anti-cancer and cardio-protective profile is a unique competitive advantage, and how close the company is to moving into the clinic once funding triggers are met.

Dr Tillett also outlines the significance of Race’s upcoming Phase 3 AML trial, the benefits of orphan drug designation, and the major milestones investors should watch in 2026 as the company prepares for a surge in clinical activity.

Watch the video to learn the details.

This video was developed in collaboration with Race Oncology, a Stockhead client at the time of publishing.

The interviews and discussions in this video are opinions only and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions.